四因子凝血酶原复合物浓缩物在Xa因子抑制剂相关颅内出血中的疗效
本研究为回顾性队列研究,纳入59例因Xa因子抑制剂相关急性颅内出血接受4FPCC逆转的患者,平均年龄78.5±10.9岁,56%为男性,阿哌沙班最常见(67.8%)。4FPCC平均剂量46.6±8.2 U/kg,88%的患者止血结局评为优良(基于Annexxa-4标准评估血肿扩大),生存率89.8%,血栓事件7例(11.9%)。作者认为4FPCC似乎是有效且安全的选择,结局与andexanet alfa相当,但需前瞻性评估及成本分析。
要点
- 59例Xa因子抑制剂相关颅内出血患者接受4FPCC平均剂量46.6±8.2 U/kg,88%止血结局为优良。
- 出院前生存率89.8%,30天内血栓事件7例(11.9%)。
- 阿哌沙班为最常见相关药物(67.8%),81.3%患者因房颤卒中预防用药。
- 作者认为4FPCC似乎有效且安全,结局与andexanet alfa相当,但需前瞻性评估。
适用人群与场景
- 因Xa因子抑制剂相关急性颅内出血接受4FPCC逆转的患者;平均年龄78.5±10.9岁,56%男性;81.3%因房颤卒中预防用药;最常见出血类型为脑出血(52.5%)。
诊断标准与关键阈值
- 止血疗效判定采用密切参照Annexxa-4的标准:优良为血肿扩大<20%,良好为>20%但≤35%,差为>35%,由两名神经重症主治医师独立评分。
处置流程与药物剂量
- 4FPCC平均剂量46.6±8.2 U/kg用于逆转Xa因子抑制剂相关颅内出血。
研究设计与关键结果
- 回顾性队列研究,59例患者,4FPCC平均剂量46.6±8.2 U/kg,88%止血结局为优良或良好,评分者间信度优良。
- 出院前生存率89.8%,30天内血栓事件7例(11.9%)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为4FPCC似乎是Xa因子抑制剂相关颅内出血的有效且安全选择,结局与andexanet alfa相当;作者建议需前瞻性评估该策略并与andexanet alfa比较,包括成本分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Intracranial bleeding (ICB) is a feared complication of systemic anticoagulation. Factor Xa inhibitors (FXaI) are used frequently due to their improved safety profile and predictable kinetics. Andexanet alfa was recently approved for emergent reversal of FXaI agents but was not compared formally to 4-Factor Prothrombin Complex Concentrates (4FPCC) which are the current standard of care in many centers. The objective of this study is to formally evaluate the hemostatic efficacy of 4FPCC in patients with FXaI-associated ICB.
METHODS: We performed a retrospective cohort study of patients receiving 4FPCC for the reversal of a FXaI in the setting of acute ICB. Hemostatic efficacy was adjudicated via evaluation of post-4FPCC CT scan using the criteria closely mirroring those outlined in Annexa-4 (excellent < 20% expansion, good > 20% but ≤ 35% expansion, poor > 35% expansion). Each image was reviewed by two neurointensivist attendings for grading. Mortality was assessed until date of discharge. Charts were screened for thrombotic events out to 30 days post-4FPCC administration.
RESULTS: A total of 59 patients were included in the final analysis. The mean age in years was 78.5 ± 10.9 and 56% were male. Apixaban was the most common FXaI prescribed at the time of presentation (67.8%). Most patients were on FXaI therapy for stroke prevention in the setting of atrial fibrillation (81.3%). Median Glasgow Coma Scale at presentation was 15(IQR 12-15), with the most frequently presenting ICB type being intracerebral hemorrhage (52.5%). The mean dose of 4FPCC prescribed was 46.6 (± 8.2) units/kg. Of those receiving 4FPCC for FXaI ICB, 88% were graded as having an excellent or good hemostatic outcome with excellent interrater reliability. Survival was high at 89.8%, and thrombotic events were seen in seven patients (11.9%).
CONCLUSION: 4FPCC appears to be an effective and safe option for FXaI-associated ICB with outcomes comparable to andexanet alfa. A formal prospective evaluation of this strategy versus andexanet alpha including cost analysis is warranted.
参考来源
- Korobey MJ, Sadaka F, Javed M, et al. Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding. Neurocrit Care. 2021. PMID: 32430804. doi:10.1007/s12028-020-00968-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。